Mitochondrial dysfunction in neurodegenerative diseases

Biochimica et Biophysica Acta - Bioenergetics

Volumn 1366, Issue 1-2, 1998, Pages 211-223

  Beal, M Flint ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Friedreich's ataxia; Huntington's disease; Mitochondrion; Oxidative damage

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; CELL PROTEIN; CREATINE; CYTOCHROME C OXIDASE; FREE RADICAL; HUNTINGTIN; IRON; MITOCHONDRIAL PROTEIN; SCAVENGER; SUPEROXIDE DISMUTASE; UBIDECARENONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME DEFICIENCY; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; IRON TRANSPORT; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NERVE DEGENERATION; NONHUMAN; ORAL DRUG ADMINISTRATION; POINT MUTATION; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ATAXIA; MUS MUSCULUS;

EID: 0032504710     PISSN: 00052728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2728(98)00114-5     Document Type: Article

References (125)

1. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons. J. Am. Med. Assoc. 262:1989;2551-2556.
2. Edland S.D., Silverman J.M., Peskind E.R., Tsuang D., Wijsman E., Morris J.C. Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology. 47:1996;254-256.
3. Duara R., Lopez-Alberola R.F., Barker W.W., Loewenstein D.A., Zatinsky M., Eisdorfer C.E., Weinberg G.B. A comparison of familial and sporadic Alzheimer's disease. Neurology. 43:1993;1377-1384.
4. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42:1997;85-94.
5. Kennedy A.M., Frackowiak R.S.J., Newman S.K., Bloomfield P.M., Seaward J., Roques P., Lewington G., Cunningham V.J., Rossor M.N. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 186:1995;17-20.
6. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. New Engl. J. Med. 334:1996;752-758.
7. Fukuyama H., Ogawa M., Yamauchi H., Yamaguchi S., Kimura J., Yonekura Y., Konishi J. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J. Nucl. Med. 35:1994;1-6.
8. Hoyer S. Intermediary metabolism disturbance in AD/SDAT and its relation to molecular events. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 17:1993;199-228.
9. Ogawa M., Fukuyama H., Ouchi Y., Yamauchi H., Kimura J. Altered energy metabolism in Alzheimer's disease. J. Neurol. Sci. 139:1996;78-82.
10. Sims N.R., Finegan J.M., Blass J.P., Bowen D.M., Nearly D. Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res. 436:1987;30-38.
11. Pettegrew J.W., Klunk W.E., Kanal E., Panchalingam K., McClure R.J. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol. Aging. 16:1995;973-975.
12. 31P NMR profiles of Alzheimer disease and multiple subcortical infarct dementia. Neurology. 39:1989;1423-1427.
13. Smith C.D., Pettigrew L.C., Avison M.J., Kirsch J.E., Tinkhtman A.J., Schmitt F.A., Wermeling D.P., Wekstein D.R., Markesberry W.R. Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. Ann. Neurol. 38:1995;194-201.
14. Parker W.D. Jr., Boyson S.J., Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:1989;719-723.
15. Van Zuylen A.J., Bosman G.J.C.G.M., Ruitenbeek W., Van Kalmthout P.J.C., De Grip W.J. No evidence for reduced thrombocyte cytochrome oxidase activity in Alzheimer's disease. Neurology. 42:1992;1246-1247.
16. Parker W.D., Parks J., Filley C.M., Kleinschmidt-DeMasters B.K. Electron transport chain defects in Alzheimer's disease brain. Neurology. 44:1994;1090-1096.
17. Mutisya E.M., Bowling A.C., Beal M.F. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J. Neurochem. 63:1994;2179-2184.
18. Kish S.J., Bergeron C., Rajput A., Dozic S., Mastrogiacomo F., Chang L.J., Wilson J.M., DiStefano L.M. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem. 59:1992;776-779.
19. King M.P., Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 246:1989;500-503.
20. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiari L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90:1997;537-548.
21. Swerdlow R.H., Parks J.K., Cassarino D.S., Maguire D.J., Maguire R.S., Bennett J.P. Jr., Davis R.E., Parker W.D. Jr. Cybrids in Alzheimer's disease: a cellular model of the disease? Neurology. 49:1997;918-925.
22. J.P. Sheehan, R.H. Swerdlow, S.W. Miller, R.E. Davis, J.K. Parks, W.D. Parker, J.B. Tuttle, Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J. Neurosci. in press (1997).
23. 2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA. 91:1994;534-538.
24. Huang H.M., Toral-Barza L., Thaler H., Tofel-Grehl B., Gibson G.E. Inositol phosphates and intracellular calcium after bradykinin stimulation in fibroblasts from young, normal aged and Alzheimer donors. Neurobiol. Aging. 12:1991;469-473.
25. Gibson G.E., Zhang H., Toral-Barza L., Szolosi S., Tofel-Grehl B. Calcium stores in cultured fibroblasts and their changes with Alzheimer's disease. Biochim. Biophys. Acta. 1316:1996;71-77.
26. Kumura E., Kosaka H., Shiga T., Yoshimine T., Hayakawa T. Elevation of plasma nitric oxide end products during focal cerebral ischemia and reperfusion in the rat. J. Cereb. Blood Flow Metab. 14:1994;487-491.
27. Moudy A.M., Handran S.D., Goldberg M.P., Ruffin N., Karl I., Kranz-Eble P., DeVivo D.C., Rothman S.M. Abnormal calcium homeostasis and mitochondrial polarization in a human encephalomyopathy. Proc. Natl. Acad. Sci. USA. 92:1995;729-733.
28. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36:1994;747-751.
29. Beal M.F. Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
30. Lyras L., Cairns N.J., Jenner A., Jenner P., Halliwell B. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68:1997;2061-2069.
31. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S.P., Wu J.F., Carney J.M., Lovell M., Markesbery W.R., Butterfield D.A. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65:1995;2146-2156.
32. Smith M.A., Sayre L.M., Anderson V., Richey P.L., Beal M.F., Kowall N., Perry G. In situ detection of oxidative modifications in Alzheimer's disease. Nature. 382:1996;120-121.
33. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17:1997;2653-2657.
34. Smith M.A., Kutty R.K., Richey P.L., Yan S.-D., Stern D., Chader G.J., Wiggert B., Petersen R.B., Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145:1994;42-47.
35. Yan S.-D., Chen X., Schmidt A.-M., Brett J., Godman G., Zou Y.-S., Scott C.W., Caputo C., Frappier T., Smith M.A., Perry G., Yen S.-H., Stern D. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA. 91:1994;7787-7791.
36. Good P.F., Werner P., Hsu A., Olanow C.W., Perl D.P. Evidence for neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol. 149:1996;21-28.
37. Schipper H.M., Cisse S., Stopa E.G. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Ann. Neurol. 37:1995;758-768.
38. Sayre L.M., Zelasko D.A., Harris P.L.R., Perry G., Salomon R.G., Smith M.A. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68:1997;2092-2097.
39. Gabuzda D., Busciglio J., Chen L.B., Matsudaira P., Yankner B.A. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 269:1994;13623-13628.
40. Gasparini L., Racchi M., Benussi L., Curti D., Binetti G., Bianchetti A., Trabucchi M., Govoni S. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci. Lett. 231:1997;113-117.
41. Ohyagi Y., Younkin S.G. Hydrogen peroxide induces Aβ accumulation in neurons. Soc. Neurosci. Abstr. 22:1996;1207.
42. Frederikse P.H., Garland D., Zigler J., Piatigorsky S.J. Oxidative stress increases production of β-amyloid (Aβ) in mammalian lenses, and Aβ has toxic effects on lens epithelial cells. J. Biol. Chem. 271:1996;10169-10174.
43. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature. 378:1995;776-779.
44. Dyrks T., Dyrks E., Masters C.L., Beyreuther K. Amyloidogenicity of rodent and human βA4 sequences. FEBS Lett. 324:1993;231-236.
45. Dyrks T., Dyrks E., Hartmann T., Masters C., Beyreuther K. Amyloidogenicity of βA4 and βA4-bearing amyloid protein precursor fragments by metal-catalyzed oxidation. J. Biol. Chem. 267:1992;18210-18217.
46. Troncoso J.C., Sukhov R.R., Kawas C.H., Koliatsos V.E. In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: correlations with senile plaques and disease progression. J. Neuropathol. Exp. Neurol. 55:1996;1134-1142.
47. Schweers O., Mandelkow E.-M., Biernat J., Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein τ controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci. USA. 92:1995;8463-8467.
48. erk2. J. Neurochem. 64:1995;2203-2212.
49. Luo Y., Bond J.D., Ingram V.M. Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases. Proc. Natl. Acad. Sci. USA. 94:1997;9705-9710.
50. Campuzano V., Montermini L., Molto M.D., Pianese L., Cossee M., Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A., Zara F., Canizares J., Koutnikova H., Bidichandani S.I., Gellera C., Brice A., Trouillas P., De Michele G., Filla A., De Frutos R., Palau F., Patel P.I., Di Donato S., Mandel J.-L., Cocozza S., Koenig M., Pandolfo M. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 271:1996;1423-1427.
51. Koutnikova H., Campuzano V., Foury F., Dolle P., Cazzalini O., Koenig M. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nature Genet. 16:1997;345-351.
52. Babcock M., de Silva D., Oaks R., Davis-Kaplan S., Jiralerspong S., Montermini L., Pandolfo M., Kaplan J. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 276:1997;1709-1712.
53. Priller J., Scherzer C.R., Faber P.W., MacDonald M.E., Young A.B. Frataxin gene of Friedreich's ataxia is targeted to mitochondria. Ann. Neurol. 42:1997;265-269.
54. Wilson R.B., Roof D.M. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nature Genet. 16:1997;352-357.
55. Rotig A., de Lonlay P., Chretien D., Foury F., Koenig M., Sidi D., Munnich A., Rustin P. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature Genet. 17:1997;215-217.
56. Ouahchi K., Arita M., Kayden H., Hentati F., Hamida M.B., Sokol R., Arai H., Inoue K., Mandel J.-L., Koenig M. Ataxia with isolated vitamin E deficiency is caused by mutations in the α-tocopheral transfer protein. Nature Genet. 9:1995;141-145.
57. Tamaru Y., Hirano M., Kusaka H., Ito H., Imai T., Ueno S. α-Tocopherol transfer protein gene: exon skipping of all transcripts causes ataxia. Neurology. 49:1997;584-588.
58. 101Gln mutation of the α-tocopherol transfer protein gene. Ann. Neurol. 41:1997;826-832.
59. Junck L., Gilman S., Gebarski S.S., Koeppe R.A., Kluin K.J., Markel D.S. Structural and functional brain imaging in Friedreich's ataxia. Arch. Neurol. 51:1994;349-355.
60. Finocchiaro G., Baio G., Micossi P., Pozza G., Di Donato S. Glucose metabolism alterations in Friedreich's ataxia. Neurology. 38:1988;1292-1296.
61. Mastrogiacomo F., LaMarche J., Dozic S., Lindsay G., Bettendorff L., Robitaille Y., Schut L., Kish S.J. Immunoreactive levels of α-ketoglutarate dehydrogenase subunits in Friedreich's ataxia and spinocerebellar ataxia type 1. Neurodegeneration. 5:1996;27-33.
62. Browne S.E., Bowling A.C., MacGarvey U., Beal M.F. Oxidative DNA damage and impaired mitochondrial metabolism in Huntington's disease. Soc. Neurosci. Abstr. 21:1995;489.
63. Rosen D.R., Siddique T., Patterson D., Figiewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.-X., Rhmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi R.E., Halperin J.J., Herzfeldt B., Van den Bergh R., Hung W.-Y., Bird T., Deng G., Mulder D.W., Smyth C., Laing N.G., Soriano E., Pericak-Vance M.A., Haines J., Rouleau G.A., Gusella J.S., Horvitz H.R., Brown R.H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:1993;59-62.
64. Bowling A.C., Barkowski E.E., McKenna-Yasek D., Sapp P., Horvitz H.R., Beal M.F., Brown R.H. Superoxide dismutase concentration and activity in familial amyotrophic lateral sclerosis. J. Neurochem. 64:1995;2366-2369.
65. Wong P.C., Pardo C.A., Borchelt D.R., Lee M.K., Copeland N.G., Jenkins N.A., Sisodia S.S., Cleveland D.W., Price D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 14:1995;1105-1116.
66. Ripps M.E., Huntley G.W., Hof P.R., Morrison J.H., Gordon J.W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 92:1995;689-693.
67. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.-X., Chen W., Zhai P., Sufit R.L., Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 264:1994;1772-1775.
68. Borchelt D.R., Lee M.K., Lunt H.S., Guarnieri M., et al. Superoxide dismutase 1 with mutations linked to familial amyotrophic lateral sclerosis possesses significant activity. Proc. Natl. Acad. Sci. USA. 91:1994;8292-8296.
69. Lyons T.J., Liu H., Goto J.J., Nersissian A., Roe J.A., Graden J.A., Cafe C., Ellerby L.M., Bredesen D.E., Butler-Gralla E., Selverstone-Valentine J. Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein. Proc. Natl. Acad. Sci. USA. 93:1996;12240-12244.
70. Beckman J.S., Crow J.P. Pathological implications of nitric oxide superoxide and peroxynitrite formation. Biochem. Soc. Trans. 21:1993;330-334.
71. Wiedau-Pazos M., Goto J.J., Rabizadeh S., Gralla E.B., Roe J.A., Lee M.K., Valentine J.S., Bredesen D.E. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science. 271:1996;515-518.
72. m for hydrogen peroxide. Proc. Natl. Acad. Sci. USA. 93:1996;5709-5714.
73. m for hydrogen peroxide. J. Biol. Chem. 272:1997;8861-8863.
74. R.J. Ferrante, L.A. Shinobu, J.B. Schulz, R.T. Matthews, C.E. Thomas, N.W. Kowall, M.E. Gurney, M.F. Beal. Increased 3-nitrotyrosine and oxidative damage in mice with a human Cu,Zn superoxide dismutase mutation. Ann. Neurol. 42:1997;326-334.
75. Bruijn L.I., Beal M.F., Becher M.W., Schulz J.B., Wong P.C., Price D.L., Cleveland D.W. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc. Natl. Acad. Sci. USA. 94:1997;7606-7611.
76. Bowling A.C., Schulz J.B., Brown R.H., Beal M.F. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J. Neurochem. 61:1993;2322-2325.
77. 2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett. 414:1997;365-368.
78. Hatazawa J., Brooks R.A., Dalakas M.C., Mansi L., Di Chiro G. Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: A PET study. J. Comput. Assist. Tomogr. 12:1988;630-636.
79. Dalakas M.C., Hatazawa J., Brooks R.A., Di Chiro G. Lowered cerebral glucose utilization in amyotrophic lateral sclerosis. Ann. Neurol. 22:1987;580-586.
80. Swerdlow R.H., Parks J.K., Miller S.W., Davis R.F., Pattee G., Parker W.D. Evidence of genetic mitochondrial pathology in sporadic amyotrophic lateral sclerosis. Soc. Neurosci. Abstr. 22:1996;2413.
81. Curti D., Malaspina A., Facchetti G., Camana C., Mazzini L., Tosca P., Zerbi F., Ceroni M. Amyotrophic lateral sclerosis: Oxidative energy metabolism and calcium homeostasis in peripheral blood lymphocytes. Neurology. 47:1996;1060-1064.
82. Siklos L., Engelhardt J., Harati Y., Smith R.G., Joo F., Appel S.H. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann. Neurol. 39:1996;203-219.
83. Sasaki S., Iwata M. Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology. 47:1996;535-540.
84. Sasaki S., Maruyama S., Yamane K., Sakuma H., Takeishi M. Ultrastructure of swollen proximal axons of anterior horn neurons in motor neuron disease. J. Neurol. Sci. 97:1990;233-240.
85. Masui Y., Mozai T., Kakehi K. Functional and morphometric study of the liver in motor neuron disease. J. Neurol. 232:1985;15-19.
86. Hirano A. Cytopathology in amyotrophic lateral sclerosis. Adv. Neurol. 56:1991;91-101.
87. Shaw P.J., Ince P.G., Falkous G., Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann. Neurol. 38:1995;691-695.
88. Beal M.F., Ferrante R.J., Browne S.E., Matthews R.T., Kowall N.W., Brown R.H. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 42:1997;646-654.
89. Shibata N., Hirano A., Kobayashi M., Siddique T., Deng H.-X., Hung W.-Y., Kato T., Asayama K. Intense superoxide dismutase-1 immunoreactivity in intracytoplasmic hyaline inclusions of familial amyotrophic lateral sclerosis with posterior column involvement. J. Neuropathol. Exp. Neurol. 55:1996;481-490.
90. Rouleau G.A., Clark A.W., Rooke K., Pramatarova A., Krizus A., Suchowersky O., Julien J.-P., Figlewicz D. SOD1 mutation is associated with accumulation of neurofilaments in amyotrophic lateral sclerosis. Ann. Neurol. 39:1996;128-131.
91. Crow J.P., Ye Y.Z., Strong M., Kirk M., Barnes S., Beckman J.S. Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L. J. Neurochem. 69:1997;1945-1953.
92. Crow J.P., Sampson J.B., Zhuang Y., Thompson J.A., Beckman J.S. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J. Neurochem. 69:1997;1936-1944.
93. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.-P., Gusella J.F., Joyner A.L., MacDonald M.E. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. 269:1995;407-410.
94. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
95. Jenkins B., Koroshetz W., Beal M.F., Rosen B. Evidence for an energy metabolism defect in Huntington's disease using localized proton spectroscopy. Neurology. 43:1993;2689-2695.
96. Martin W.R.W., Hanstock C., Hodder J., Allen P.S. Brain energy metabolism in Huntington's disease measured with in vivo proton magnetic resonance spectroscopy. Ann. Neurol. 40:1996;538.
97. Harms L., Meierkord H., Timm G., Pfeiffer L., Ludolph A.C. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J. Neurol. Neurosurg. Psychiatry. 62:1997;27-30.
98. 10. Ann. Neurol. 41:1997;160-165.
99. Obrien C.F., Miller C., Goldblatt D., Welle S., Forbes G., Lipinski B., Panzik J., Peck R., Plumb S., Oakes D., Kurlan R., Shoulson I. Extraneural metabolism in early Huntington's disease. Ann. Neurol. 28:1990;300-301.
100. Matsuishi T., Sakai T., Naito E., Nagamitsu S., Kuroda Y., Iwashita H., Kato H. Elevated cerebrospinal fluid lactate/pyruvate ratio in Machado-Joseph disease. Acta Neurol. Scand. 93:1996;72-75.
101. Butterworth J., Yates C.M., Reynolds G.P. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and γ-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J. Neurol. Sci. 67:1985;161-171.
102. Stahl W.L., Swanson P.D. Biochemical abnormalities in Huntington's chorea brains. Neurology. 24:1974;813-819.
103. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H.V. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39:1996;385-389.
104. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M.K., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41:1997;646-653.
105. Bourgeron T., Rustin P., Chretien D., Birch-Machin M., Bourgeois M., Viegas-Pequignot E., Munnich A., Rotig A. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nature Genet. 11:1995;144-149.
106. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. USA. 92:1995;7105-7109.
107. Gutekunst C.-A., Peng T.-I., Whaley W.L., Rock B., Hersch S.M., Greenamyre J.T. Mitochondrial calcium homeostasis in Huntington's disease fibroblasts. Soc. Neurosci. Abstr. 22:1996;227.
108. Burke J.R., Enghild J.J., Martin M.E., Jou Y.-S., Myers R.M., Roses A.D., Vance J.M., Strittmatter W.J. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nature Med. 2:1996;347-350.
109. Matthews R.T., Yang L., Beal M.F. S-methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity. Exp. Neurol. 143:1997;282-286.
110. Ferrante R.J., Kowall N.W., Hersch S.M., Brown R.H., Beal M.F. Immunohistochemical localization of markers for oxidative injury in Huntington's disease. Soc. Neurosci. Abstr. 22:1996;227.
111. Beal M.F. Huntington's disease, energy and excitotoxicity. Neurobiol. Aging. 15:1994;275-276.
112. Ludolph A., Seelig M., Ludolph A., Novitt P., Allen C.N., Spencer P.S., Sabri M.I. 3-Nitropropionic acid: exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 18:1992;492-498.
113. Palfi S., Ferrante R.J., Brouillet E., Beal M.F., Dolan R., Guyoi M.C., Peschanski M., Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 16:1996;3019-3025.
114. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
115. Favit A., Nicoletti F., Scapagnini U., Canonico P.L. Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration. J. Cereb. Blood Flow Metab. 12:1992;638-645.
116. 10 attenuates the MPTP induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 783:1997;109-114.
117. Schulz J.B., Huang P.L., Matthews R.T., Passov D., Fishman M.C., Beal M.F. Striatal malonate lesions are attenuated in neuronal nitric oxide knockout mice. J. Neurochem. 67:1996;430-433.
118. Hemmer W., Wallimann T. Functional aspects of creatine kinase in brain. Dev. Neurosci. 15:1993;249-260.
119. Dunant Y., Loctin F., Marsal J., Muller D., Parducz A., Rabasseda X. Energy metabolism and quantal acetylcholine release: effects of botulinum toxin, 1-fluoro-2,4-dinitrobenzene, and diamide in the Torpedo electric organ. J. Neurochem. 50:1988;431-439.
120. Kaldis P., Hemmer W., Zanolla E., Holtzman D., Wallimann T. 'Hot spots' of creatine kinase localization in brain: cerebellum, hippocampus and choroid plexus. Dev. Neurosci. 18:1996;542-554.
121. Sauter A., Rudin M. Determination of creatine kinase parameters in rat brain by NMR magnetization transfer: correlation with brain function. J. Biol. Chem. 268:1993;13166-13171.
122. 31P NMR magnetization transfer. J. Cereb. Blood Flow Metab. 14:1994;1070-1077.
123. Kernec F., Le Tallec N., Nadal L., Begue J.-M., Le Rumeur E. Phosphocreatine synthesis by isolated rat skeletal muscle mitochondria is not dependent upon external ADP: a 31P NMR study. Biochem. Biophys. Res. Commun. 225:1996;819-825.
124. Xu C.J., Klunk W.E., Kanfer J.N., Xiong Q., Miller G., Pettegrew J.W. Phosphocreatine-dependent glutamate uptake by synaptic vesicles. J. Biol. Chem. 271:1996;13435-13440.
125. Matthews R.T., Yang L., Jenkins B.G., Ferrante R.J., Rosen B.R., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 18:1998;156-163.